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Abstract
Background and Purpose—White matter lesion (WML) progression on magnetic resonance 
imaging (MRI) is related to cognitive decline and stroke, but its determinants besides baseline 
WML burden are largely unknown. Here, we estimated heritability of WML progression, and 
sought common genetic variants associated with WML progression in elderly participants from 
the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium.
Methods—Heritability of WML progression was calculated in the Framingham Heart Study. The 
genome-wide association study included 7773 elderly participants from 10 cohorts. To assess the 
relative contribution of genetic factors to progression of WML, we compared in seven cohorts risk 
models including demographics, vascular risk factors plus single nucleotide polymorphisms 
(SNPs) that have been shown to be associated cross-sectionally with WML in the current and 
previous association studies.
Results—A total of 1085 subjects showed WML progression. The heritability estimate for WML 
progression was low at 6.5%, and no SNPs achieved genome-wide significance (p-value < 
5×10−8). Four loci were suggestive (p-value < 1×10−5) of an association with WML progression: 
10q24.32 (rs10883817, p=1.46×10−6); 12q13.13 (rs4761974, p=8.71×10−7); 20p12.1 (rs6135309, 
p=3.69×10−6); and 4p15.31 (rs7664442, p=2.26×10−6). Variants that have been previously related 
to WML explained only 0.8% to 11.7% more of the variance in WML progression than age, 
vascular risk factors and baseline WML burden.
Conclusions—Common genetic factors contribute little to the progression of age-related WML 
in middle-aged and older adults. Future research on determinants of WML progression should 
focus more on environmental, life-style or host-related biological factors.
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Introduction
The etiology of white matter lesions (WML) on magnetic resonance imaging (MRI) is still 
incompletely understood. WML burden was shown to be highly heritable.1-3 Age and 
hypertension are the main known risk factors for WML but explain only a small proportion 
of lesion presence and burden.4 Prior to the era of genome-wide association studies (GWAS) 
candidate gene studies investigated variants in 19 genes and found associations between 
WML extent and polymorphisms in the apolipoprotein E, the methylentetrahydrofolate 
reductase, the angiotensin-converting enzyme and the angiotensinogen genes.5, 6 Moreover, 
genetic variants in the NOTCH3 gene may not only play a role in CADASIL, a monogenic 
cerebral small vessel disease, but are also likely to be involved in the etiology of age-related 
WML burden.7 In 2011, the Cohorts for Heart and Aging Research in Genomic 
Epidemiology (CHARGE) Consortium8 performed the first genome-wide association study 
on WML burden in the general population.9 The CHARGE investigators identified 6 SNPs 
mapping to a locus on chromosome 17q25 to be related to WML burden. The findings of the 
discovery meta-analyses had been confirmed in an independent sample of 1607 AGES-
Reykjavik participants and in 1417 and 1677 elderly white participants from the Three-City-
Dijon Study9 and the Rotterdam Study III10 as well as in a study of WML burden in persons 
with a clinical ischemic stroke.11 The association was also confirmed in an Asian population 
including 1190 Japanese persons with a mean age of 66 years.12 The region on chromosome 
17 is approximately 100 kb long and harbors several genes with diverse functions such as 
the 2 tripartite motif-containing genes (TRIM65 and TRIM47) the WW domain binding 
protein 2 gene (WBP2), the mitochondrial ribosomal protein L38 gene (MRPL38), the Fas-
binding factor 1 gene (FBF1), the acyl-coenzyme A oxidase 1 gene (ACOX1) and the C-
Elegans homolog (UNC13D) gene. Although genetic factors may play an important role in 
the occurrence of WML in middle-aged to older adults, whether these genes or others 
influence the further progression of WML is unknown. Using data on WML progression 
from all the cohorts currently available within the CHARGE consortium, we examined the 
heritability of WML progression and performed a meta-analysis of GWAS data in 7773 
individuals of European descent from 10 cohorts to identify common single nucleotide 
polymorphisms (SNPs) that influence the risk for WML progression. We also assessed the 
relative contribution of genetic factors in predicting WML progression beyond information 
that can be obtained from baseline clinical and MRI data alone.
Materials and Methods
Study Population
Study participants were from 10 prospective cohort studies collaborating in the CHARGE 
Consortium8: the Aging Gene-Environment Susceptibility Reykjavik Study (AGES-
Reykjavik)13, the Atherosclerosis Risk in Communities (ARIC) study14, the Austrian Stroke 
Prevention Study (ASPS)15, 16, the Cardiovascular Health Study (CHS)17, the Framingham 
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Heart Study (FHS)18, 19, the Prospective Study of Pravastatin in the Elderly at Risk 
(PROSPER)20, 21, the Rotterdam Study II (RS II ) and the Rotterdam Study III (RS III)22, 
the Tasmanian Study of Cognition and Gait (TASCOG)23 and the 3C-Dijon study.24 All 
participating studies agreed on phenotype harmonization, covariate selection, pre-specified 
analytic plans for within-study analyses, and meta-analysis of results. Each study secured 
approval from Institutional Review Boards, and all participants provided written informed 
consent for study participation, MRI scanning, and use of DNA for genetic research.
Participants were eligible for the current study if they had genotyping, serial MRI, and 
lacked a history of transient ischemic attacks, strokes, dementia, or any combination of these 
conditions. All the individuals in the present analysis were whites of European descent. The 
number of participants and their characteristics in each cohort are shown in Supplemental 
Table I in the online-only Data Supplement.
WML Progression Assessment
In each study, eligible participants were invited to undergo serial MRI scans, which were 
performed and interpreted in a standardized fashion without knowledge of demographic, 
clinical or genetic information (Section II in the online-only Data Supplement). Except for 
ARIC and CHS whose readers used a 10-point scale, readers in the other cohorts measured 
the volume of WML on each MRI scan. WML progression was defined as absent or present 
(Section III in the online-only Data Supplement). In brief, WML progression was considered 
to be present if visual rating increased by at least 1 grade between baseline and follow-up in 
ARIC and CHS, or if WML volume increased by at least one standard deviation of the 
study-specific mean of volume change in AGES-Reykjavik, ASPS, FHS, PROSPER, RS II, 
RS III, TASCOG and 3C-Dijon. WML regression was rare in all studies and was not 
considered separately in these analyses.
Genotyping
The consortium was formed after individual studies had finalized their GWAS platforms, 
which differed across studies. All studies used their genotype data to impute to the 2.5 
million non-monomorphic, autosomal, single nucleotide polymorphisms (SNPs) described 
in HapMap’s European population panel. Extensive quality control analyses were performed 
in each cohort. Details on the genotyping, quality control and imputation efforts are 
described in Supplemental Tables II - IV in the online-only Data Supplement.
Heritability of WML Progression
Heritability of WML progression was calculated based on family structure in FHS, which is 
the only family study among the participating cohorts. Calculations were based on annual 
WML change and two models were assessed. The first model adjusted for age and sex, 
while the second model additionally adjusted for WML volume at baseline. The ratio of the 
genetic variance to the phenotypic variance in FHS was determined using variance 
component models in SOLAR.25
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Genome-wide association analyses (GWAS)
For the GWAS each study fitted an additive genetic model with a 1-degree-of-freedom trend 
test relating genotype dosage, 0 to 2 copies of the minor allele, to presence or absence of 
WML progression. We used logistic regression models to calculate regression estimates 
with corresponding standard errors. Initial analyses were adjusted for age, sex, interval 
between scans as well as principal components of populatsion structure if appropriate. 
Subsequent analyses included additional adjustment for WML volume at baseline. In 
addition, ARIC and CHS also adjusted for study site, and FHS, for familial structure. We 
then conducted a meta-analysis of logistic regression estimates and standard errors using a 
fixed effects inverse-variance weighting approach with genomic control correction as 
implemented in METAL.26
There was no evidence of inflated test statistics in the individual cohort analyses (Figures I 
and II in the online-only Data Supplement).
The genome-wide significance threshold was set a priori at 5×10−8. Associations were 
considered highly suggestive for SNPs with 5×10−8<p<1×10−5.
To evaluate if the lengths of the observational period influenced the effect size of highly 
suggestive SNPs and WML progression we performed GWAS meta-analyses separately for 
cohorts with short mean follow-up and those with long mean follow-up time. Short-term 
studies were AGES-Reykjavik, PROSPER and TASCOG. Long-term cohorts were ARIC, 
ASPS, CHS and FHS (for follow-up intervals between scans see Supplemental Table I in the 
online-only Data Supplement). Identical analyses were also done for younger (ARIC, ASPS, 
FHS, RSII and RSIII) and older (AGES-Reykjavik, CHS, PROSPER, TASCOG and 3C-
Dijon) cohorts (for mean age of cohorts see Supplemental Table I in the online-only Data 
Supplement). The meta-analysis regression coefficients β of the SNPs were then compared 
between the investigational subsets using a z-test.
Annotation
Key SNPs were functionally annotated with SNPnexus27 and ANNOVAR.28 The SNAP29 
web application of the Broad Institute was used to determine linkage-disequilibrium (LD). 
Regional association plots were generated with LocusZoom.30 Furthermore we used the 
NCBI Genotype-Tissue Expression eQTL Browser31 to check if a given SNP was associated 
with a quantitative gene expression trait.
Performance of WML progression risk models
To estimate the relative importance of genetic factors for progression of WML we compared 
the explained variance between three models in ASPS, CHS, FHS, PROSPER, RS II, RS III, 
and 3C-Dijon. Model 1 served as the reference and included age, sex, hypertension, 
diabetes, current smoking and the time interval between scans; model 2 included model 1 
variables and those SNPs with the lowest p-value at each highly suggestive locus according 
to the present GWAS meta-analysis with adjustment for WML burden at baseline. We also 
included a missense SNP identified by annotation analyses. Model 3 included all model 2 
variables plus genetic polymorphisms which were shown to be associated with WML in 
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previous publications.5, 7, 9, 32-43 We included only those SNPs for which an association 
with WML was reported by at least 2 studies. In case that any of these SNPs was not present 
in our database, a proxy SNP (r2 > 0.8) was selected to be included.9 Based on this search 
strategy we selected ACE5, 32-34 (rs4343), MTHFR5, 35, 36 (rs1801133), AGT5, 37-39 
(rs2478539), TRIM479 (rs1055129), TRIM659 (rs3744028), NOTCH37 (rs10404382) and 
APOE45, 40-43 genotypes to be included in model 3. APOEε4 status was included as a binary 
variable (E4+ included the e3/e4 and e4/e4 genotypes; E4- included e2/e2, e2/e3 and e2/e4 
genotypes). The three models were also calculated with additional adjustment for WML 
volume at baseline. Models 2 and 3 were adjusted for principal components of population 
structure if appropriate. The goodness of fit for each model was assessed by Nagelkerke’s 
R2.44, 45
Results
The analyses included 7773 participants from 10 cohort studies (Supplemental Table I in the 
online-only Data Supplement). A total of 4342 (56%) of study participants were women; 
4030 (52%), hypertensive; and 690 (8.9%), diabetic. The mean systolic blood pressure 
ranged between 121.9mmHg and 157.8mmHg and the mean diastolic blood pressure 
between 69.6mmHg and 86.5mmHg. The mean time interval between the baseline and 
follow-up MRI was shortest in AGES-Reykjavik with 29.1 months and longest in ARIC 
with 123.6 months. Overall, WML progression was observed in 1085 (14.0%) study 
participants with the study-specific mean annual volume increase ranging between 0.2 cm3 
and 1.4 cm3. The association between mean WML volume at baseline and mean annual 
volume increase in our cohorts was moderate (Pearson correlation coefficient r=0.59), but 
did not reach statistical significance (p-value=0.095). The relationship for each cohort is 
displayed in Supplemental Figure III in the online-only Data Supplement.
Heritability of WML progression
After adjustment for age and sex the heritability estimate for WML progression observed in 
1368 FHS individuals was 6.5%. Additional adjustment for WML burden at baseline 
resulted in a heritability estimate of 4.7%.
Genome-wide associations of WML progression
Figure 1 illustrates the meta-analysis results of genome-wide association analyses on WML 
progression without and with adjustment for WML burden at baseline. In both meta-
analyses no SNPs achieved genome wide significance (p-value < 5×10−8). Meta-analysis 
without adjustment for WML burden at baseline revealed 45 SNPs in 7 loci on 7 
chromosomes with a highly suggestive association with WML progression at p-values < 
1×10−5 (Supplemental Table V in the online-only Data Supplement). After additional 
adjustment for WML burden at baseline, 8 highly suggestive associations were identified 
(Supplemental Table VI in the online-only Data Supplement). These SNPs are located in 6 
loci on 6 chromosomes. There is an overlap of four suggestive loci (1q41, 5q12.1, 12q13.13 
and 13q34) between the two meta-analysis results. In the meta-analysis without adjustment 
for WML burden at baseline 35 of 45 suggestive SNPs in total were located at 10q24.32. 
The SNP rs10883817 had the lowest p-value (1.46×10−6) at this locus, with an odds ratio 
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(OR) of 1.27, a mean minor allele frequency of 0.41, and a mean imputation quality score of 
0.98. The suggestive variants at locus 10q24.32 were in LD (r2 between 0.336 and 1) and 
reside either in introns of genes AS3MT, CNNM2, NT5C2, in the intergenic regions 
between these genes, or in exons of CNNM2 and NT5C2 (Figure 2 A).
At the second locus of interest, 12q13.13, we identified 3 highly suggestive variants in the 
analysis without adjustment for WML burden at baseline and only 1 with adjustment. In the 
meta-analysis without adjustment for baseline WML burden rs4761974 had the lowest p-
value (8.71×10−7), with an odds ratio of 0.5. After additional adjustment for baseline WML 
volume the p-value of the association changed to 2.94×10−6 (OR=0.5). The SNP had a mean 
minor allele frequency of 0.057 and a mean imputation quality score of 0.98. Suggestive 
SNPs at this locus were in high LD (r2 between 0.786 and 1) and are located either in introns 
or in close proximity to the gene SLC4A8 (Figure 2 B).
At the third locus 20p12.1 in the analysis without adjustment for WML burden at baseline, 
the top SNP was rs6135309 with a p-value of 3.69×10−6, an odds ratio of 0.78, a mean 
minor allele frequency of 0.29, and a mean imputation quality score of 0.97. Both suggestive 
variants at this locus were in LD (r2=0.642) and reside in introns of MACROD2 (Figure 2 
C). The fourth locus suggestive of an association with WML progression was located on 
chromosome 4p15.31 in the analysis with adjustment for WML burden at baseline. The top 
SNP at this locus was rs7664442 (p-value=2.26×10−6; OR=0.65), which had a mean minor 
allele frequency of 0.079 and a mean imputation quality score of 0.96. These three SNPs at 
4p15.31 were in perfect LD (r2=1) and are located in the intergenic region near GBA3 
(Figure 2 D).
Functional annotation of all highly suggestive SNPs and SNPs in linkage-disequilibrium 
with them was performed. The two suggestive exonic variants at locus 10q24.32, rs2275271 
(p-value=2.26×10−6, OR=0.79) and rs3740387 (p-value=5.10×10−6, OR=1.25), were 
synonymous. Two other suggestive SNPs at this locus have been reported in previous 
genome-wide association studies investigating schizophrenia46-48 (rs7897654; p-
value=5.26×10−6, OR=0.79 and rs7914558; p-value=2.14×10−6, OR=1.26). No association 
between suggestive SNPs and quantitative gene expression traits could be determined. A 
comparison of the effect size of suggestive SNPs on WML progression between studies with 
short versus long term follow-up failed to demonstrate significantly increased effect sizes in 
studies with long-term follow-up. There were also no significant differences in the effect 
sizes of suggestive SNPs on WML progression between younger and older cohorts (data not 
shown).
Performance of WML progression risk models
As can be seen from Table 1, model 1, which included demographics and risk factors, 
explained between 2.3% and 14.9% of the variance in WML progression in the various 
cohorts. Amongst studies that assessed WML progression by volume change, 17.2% to 
43.3% of the WML progression variance was explained if baseline WML was included 
(model 1). In CHS, which used a visual rating scale for assessment of WML progression, 
only 4.5% of the variance could be explained. Highly suggestive SNPs from the current 
GWAS and all genetic variants previously described as being related to WML accounted for 
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additional 1.1% to 8.6% (model 2) and 0.8% to 11.7% (model 3) of the variance of WML 
progression beyond age, sex, vascular risk factors and baseline WML volume.
Discussion
In this first genome-wide association study on WML progression, our data indicate that 
genetic factors contribute only little to WML progression in the general elderly population. 
This conclusion relies on three major findings. First, the family-based heritability estimate 
for WML progression was only 6.5% versus a heritability of 55% for baseline WML burden 
in the same sample.2 Second, our genome-wide analysis yielded no associations at a 
genome-wide significance level. Third, risk prediction models including highly suggestive 
SNPs according to the present GWAS meta-analysis plus all genetic polymorphisms that 
have been shown to be associated with WML burden in previous literature explained only 
between 0.8% and 11.7% more of the variance of WML progression than that explained by 
baseline clinical and MRI data. These results for WML progression oppose previous cross-
sectional studies in which the contribution of genetic factors for WML burden was 
substantial.5, 7, 9, 32-43 This finding is puzzling because cross-sectionally assessed WML 
burden and WML progression are both quantitative measures with presumably the same 
biological basis. In this context it is of note, however that in our study initial burden of 
WML predicted annual WML volume increase moderately, but this relationship was not 
significant. Moreover, for both, brain volume and cognitive functions, similar results of 
limited genetic variance in longitudinal measures have been shown.49-51 In line with our 
findings on white matter lesions these investigations also found that measures of brain 
atrophy and cognitive performance assessed cross-sectionally are highly heritably but 
predominantly environmental factors account for the rate of change of these cerebral 
phenotypes over time.
We identified four suggestive loci for WML progression on chromosomes 10q24.32, 
12q13.13, 20p12.1 and 4p15.31. None of the SNPs in these loci reached genome-wide 
significance; however, some of the neighboring genes within these loci have been related to 
neuropsychiatric or vascular diseases.
Locus 10q24.32 includes AS3MT (arsenic (+3 oxidation state) methyltransferase), CNNM2 
(Cyclin M2) and NT5C2 (5′-nucleotidase, cytosolic II). These genes have previously been 
identified to be associated with schizophrenia46-48, 52, 53 and blood pressure54-57 in GWAS 
and replication studies. CNNM2 and NT5C2 were associated with coronary artery disease,58 
and CNNM2 was additionally associated with intracranial aneurysm.59 Moreover, a 
suggestive variant in an intron of AS3MT, rs10748835 (p-value=2.79×10−6, OR=1.25), is 
known to modify cognitive function in persons with low-level arsenic exposure.60
The locus at 12q13.13 includes SLC4A8, a sodium bicarbonate co-transporter of the 
designated solute carrier family 4. It transports sodium and bicarbonate ions across the cell 
membrane.61, 62 The gene is highly expressed in all major regions of the brain and is 
involved in pH regulation in human neurons.63
Hofer et al. Page 7













MACROD2 (MACRO domain containing 2) at locus 20p12.1 is a protein-coding gene that 
has been found to be associated with MRI-defined brain infarcts in a previous GWAS.64 
This is particularly intriguing as recent studies have suggested new lacunes are most likely 
to develop in areas of white matter progression.65 MACROD2 has also been associated with 
autistic traits.66
Although we included a large number of participants from ten cohort studies with 
longitudinal assessment of WML change, we cannot exclude the possibility that we missed 
significant associations of WML progression to SNPs with small effect sizes or low risk 
allele frequencies. Moreover, three other factors need to be considered when interpreting our 
results. First, we used a binary phenotype based on visual rating or cut-off values of 
volumetric change to define WML progression. This conservative definition decreased the 
likelihood of false positive ratings but, among those with WML at baseline, might have led 
to an underestimation of WML progression. Second, the average time period between scans 
among contributing cohorts was 54 months, and despite the fact that single studies had 
followed their participants for more than 10 years, it is conceivable that this period was too 
short to reveal the full impact of genetic factors on WML progression. Our findings that the 
effect sizes of suggestive GWAS SNPs on WML progression were not significantly larger in 
cohorts with long-term follow-up versus cohorts with short-term follow-up and in older 
versus younger cohorts do not support this assumption. Third, we by design concentrated on 
elderly people. Genetic factors may play a larger role for white matter progression in 
younger populations.
Our study findings have important implications for future research on age-related white 
matter changes. They suggest that, although the contribution of genetic factors seems to be 
large during the initiating phase of white matter damage, the propagating phase of WML 
appears to be mainly influenced by non-genetic determinants. With the exception of high 
blood pressure these non-genetic risk factors for WML progression remain largely 
unknown.67, 68 Based on current data, we need to intensify the search for potentially 
modifiable environmental and lifestyle factors that influence the progression of age-related 
white matter changes and the associated morbidity. Moreover, while this study focused on 
the influence of genetics on age-related WML progression, the effects of heritability on 
injury-induced WML progression are an interesting direction for future studies.
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Figure 1. Genome-wide Manhattan plot for progression of WML
The Manhattan plot for the GWAS without adjustment for WML burden at baseline is 
shown in the upper panel and the Manhattan plot for the GWAS adjusted for WML burden 
at baseline is shown in the lower panel. The plot shows the −log10(p-values) for all SNPs in 
the analysis against their genomic position. Within each chromosome, shown on the x-axis, 
the results are plotted left to right from the p-terminal end. The red line represents the 
threshold for genome wide significance (5×10−8), and the blue line represents the threshold 
for highly suggestive SNPs (1×10−5).
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Figure 2. Regional association plots for WML progression SNPs in loci 10q24.32, 12q13.13, 
20p12.1, 4p15.31
The plots for locus 10q24.32 (A) and 12q13.13 (B) are shown in the upper panel, and the 
plots for locus 20p12.1 (C) and 4p15.31 (D) are shown in the lower panel. For loci 
10q24.32, 12q13.13, and 20p12.1 associations were determined by WML progression 
GWAS meta-analysis in the model without adjustment for WML burden at baseline. For 
locus 4p15.31 the associations were determined by WML progression GWAS meta-analysis 
in the model with adjustment for WML burden at baseline. Plots are centered on the most 
significant SNP at a given locus along with the meta-analysis results for SNPs in a region 
surrounding it (± 200kb). All SNPs are plotted with their meta-analysis p-values against 
their genomic position, with the most significant SNP in the region indicated as a diamond 
and other SNPs shaded according to their pairwise correlation (r2) with the signal SNP. The 
blue line represents the estimated recombination rates. Gene annotations are shown as dark 
blue line. The boxes at the end of the genes show the 5′ and 3′ UTRs, while boxes within the 
gene represent exons. Arrows indicate the direction of transcription.
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